OnQuality Announces FDA Clearance of IND Application for OQL025
04 Jan 2024 //
PR NEWSWIRE
OnQuality Announces FDA Clearance of IND Application for OQL051
06 Jun 2023 //
PR NEWSWIRE
OnQuality Announces FDA Clearance of IND Application for OQL036
28 Apr 2023 //
PR NEWSWIRE
OnQuality Pharmaceuticals Presented Preclinical Data for OQL025 and OQL06x
18 Apr 2023 //
PR NEWSWIRE
OnQuality Announces Presentations of OQL025 and OQL06x, at the AACR
15 Mar 2023 //
PR NEWSWIRE
OnQuality Pharmaceuticals Expands Part 2 of the NOVA-II Phase 2 Trial
05 Jan 2023 //
PR NEWSWIRE
OnQuality enrols first subject in Phase II HFSR therapy trial
09 Nov 2022 //
CLINICALTRIALSARENA
OnQuality Announces the Enrollment of the First Patient in Part 2
08 Nov 2022 //
PRNEWSWIRE
OnQuality Pharma to Have Two Abstracts Published in the 2022 ASCO
27 May 2022 //
PRNEWSWIRE
OnQuality Pharma to Present PC Data for OQL051 at AACR
08 Mar 2022 //
PRNEWSWIRE
OnQuality to Present NOVA-II Phase 2 Trial Update and Oncologist Survey
14 Feb 2022 //
PRNEWSWIRE
OnQuality Pharma to Present Oncologist Survey Data at ASCO GI 2022
19 Jan 2022 //
PRNEWSWIRE
OnQuality Reports Topline Data from Phase 2 Trial for Cancer Therapy
04 Jan 2022 //
PRNEWSWIRE
OnQuality Pharmaceuticals Announces Completion of Part 1 of NOVA-II Trial
07 Sep 2021 //
PRNEWSWIRE
OnQuality Pharmaceuticals to Present on NOVA-II Trial Evaluating OQL011
18 May 2021 //
PRNEWSWIRE
OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing
31 Mar 2021 //
PRNEWSWIRE
OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing
30 Mar 2021 //
PRNEWSWIRE